NOVOCURE

Lobbying client · Pennsylvania · filed 2025 to 2026

Medical technology company.

$90,000 Reported spend

4 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 4 filings. Everything on this page is grouped by the client's LDA id (70869), not by name.

Firms hired 1

MAYER BROWN LLP $90,000 4 filings

Reported by year 2 years

2026 $60,000 2 filings
2025 $30,000 2 filings

Issues lobbied 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 4

HOUSE OF REPRESENTATIVES 3
SENATE 3
U.S. Trade Representative (USTR) 3
Food & Drug Administration (FDA) 2

Recent filings 4 total

Q2

MAYER BROWN LLP

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $20,000 income · posted Jul 20, 2026

View → Q1

MAYER BROWN LLP

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $40,000 income · posted Apr 20, 2026

View → Q4

MAYER BROWN LLP

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $30,000 income · posted Jan 21, 2026

View → RR

MAYER BROWN LLP

4th Quarter (Oct 1 - Dec 31) 2025 · posted Jan 21, 2026

View →

Foreign entities disclosed 1

NOVOCURE Switzerland named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.